Showing results (301-310 of 880) with videos related to

Sort By:
Pageof 88
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel DiseasesNghia H Nguyen, Lucila Ohno-Machado, William J Sandborn, et al.
Gastroenterology|June 10, 2006
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control studyFernando S Velayos, Edward V Loftus, Tine Jess, et al.
Inflammatory Bowel Diseases|December 11, 2008
Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL surveyDavid T Rubin, Corey A Siegel, Sunanda V Kane, et al.
Clinical Biochemistry|July 28, 2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assaysBadr Al-Bawardy, Sarah M Jenkins, Melissa R Snyder, et al.
Inflammatory Bowel Diseases|September 18, 2010
Inflammatory bowel disease and asthma: a population-based, case-control studyYilma A Fenta, Natalia Tello, Ji A Jung, et al.
Inflammatory Bowel Diseases|December 11, 2019
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel DiseaseRaseen Tariq, Molly B Disbrow, John K Dibaise, et al.
Diseases of the Colon and Rectum|October 1, 2019
Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?Amy L Lightner, Nicholas P McKenna, Ahmad Alsughayer, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 17, 2012
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopySunil Samuel, David H Bruining, Edward V Loftus, et al.
Gastroenterology|February 26, 2008
Risk factors for opportunistic infections in patients with inflammatory bowel diseaseMurat Toruner, Edward V Loftus, W Scott Harmsen, et al.
Advances in Therapy|March 30, 2026
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD TrialStefan Schreiber, Bruce E Sands, Silvio Danese, et al.
Pageof 88